An 80-year-old womanwith diabetes mellitus was treated with gliclazide. Prior to the gliclazide administration, her urinary excretion ofalbumin, serumurea nitrogen and serumcreatinine were normal. After the medication, oliguria, edema and azotemia developed. On the twenty-fourth day whenthe edemawas severe and generalized, gliclazide administration was terminated. On the following day urinary volume increased suddenly (5,740 ml/day). Polyuria persisted for five days. Edemaimproved and urea nitrogen and creatinine were normalized thereafter. Though the mechanism is not known, the clinical course suggests that gliclazide is the principal causative factor in the water retention and azotemia in this patient.
Introduction
In addition to hypoglycemia, sulfonylureas cause several adverse reactions such as hematological abnormalities, cutaneous reactions, gastrointestinal symptoms and hepatic reactions (1) . This report describes a previously unreported adverse reaction to gliclazide. Here we describe water retention with azotemia which developed in a patient with non-insulin-dependent diabetes mellitus during gliclazide treatment and disappeared rapidly after the withdrawal of the drug.
Case Report
An 80-year-old womanwith a ten-year history of diabetes mellitus was admitted to this hospital because of multiple cerebral infarction in September 1991. She had an acute myocardial infarction in 198 1. On admission HbAlc was 6.4%. She did not seem to have obvious diabetic nephropathy as indicated by normal urinary excretion of albumin (7 to 10 jug/ min), nor did she have diabetic retinopathy. She had been maintained with nasogastric tube feeding. From January to May 1992, serum urea nitrogen concentration (6 to 17 mg/dl), serum creatinine concentration (0.4 to 0.7 mg/dl), and plasma atrial natriuretic peptide (ANP) concentration (19 to 38 pg/ml) (normal range 10 to 40 pg/ml) were normal and stable. OnJune 9, 1992, her fasting plasma glucose concentration was 150 mg/dl, serum albumin 3.4 g/dl, urea nitrogen 16.6 mg/ dl, creatinine 0.6 mg/dl, Na 137 mEq/1, and K 3.7 mEq/1.
Gliclazide (20 mg/day) was started on June 27. Two days earlier, very mild edema probably due to hypoalbuminemia was noticed in the back. After the initiation of gliclazide, the edema progressively worsened (Fig. 1 ). Blood urea nitrogen and creatinine increased gradually. Twoweeks after the start of gliclazide administration when albumin was 2.5 g/dl, Na 137 mEq/1, K 3.5 mEq/1, and edema was generalized, furosemide (20 mg/day) and spironolactone (25 mg/day) were started, and the dose of gliclazide was increased to 40 mg/day. Four days later, dopamine was started. Twentydays after the initiation of gliclazide whenthe measurementof urinary volumewas started, oliguria (400 ml/day) was noticed. Serum Na was 135 mEq/1 and K was 4.2 mEq/1. Doses of furosemide and spironolactone increased 2-fold. There was no improvement in edema or urinary volume. Microscopic hematuria and columnar epithelial cells in the urinary sediment were noticed. Twenty-four days after the start of gliclazide, oliguria and hypoalbuminemia (2.5 g/dl) persisted, hyponatremia ( 1 27 mEq/1) developed, serum K was 4.3 mEqA,urea nitrogen was 49.6 mg/dl, and creatinine was 2.2 mg/dl. Plasma ANP was high (100 pg/ml), and plasma vasopressin concentration (0.8 pg/ml) was appropriate for the plasma osmolality (reference range 0.5 to 3.0 pg/ml). Urinary excretion of N-acetyl-B-D-glucosaminidase (19 U/l) was high (normal range 1 to 5 U/l). Gliclazide administration was termi- FPG: fasting plasma glucose.
nated on that day. On the following day, the urinary volume increased suddenly (5,740 ml/day). Polyuria persisted for five days. Edemaimproved and urea nitrogen and creatinine levels started to decline. Two weeks after the termination of gliclazide administration, albumin was 3.0 g/dl, urea nitrogen 1 8.7 mg/dl, creatinine 0.7 mg/dl, Na 136 mEq/1, and K 4.6 mEq/L There was no massive proteinuria, fever, rash, eosinophilia nor liver dysfunction during the clinical course. Serum Ca corrected with albumin was normal during the course. From August to October1992, serum urea nitrogen, creatinine, Na, K, and plasma ANPwere normal; urinary excretion ofN-acetyl-B-D-glucosaminidase was slightly high (6 to 1 1 U/l). Lymphocyte stimulation test with the same gliclazide agent was negative.
Discussion
The most remarkable finding in this patient is the abrupt polyuria following the withdrawal of gliclazide. Though the hypoalbuminemia probably due to malnutrition and possible heart failure might have played a role, the clinical course clearly suggests that gliclazide was the principal causative factor of the water retention. It is unlikely that the sudden 10-fold increase of urinary volume was solely due to the diuretics and dopamine which had been administered for about one to two weeks. There was no event such as termination of arrhythmia which may cause a sudden improvementin cardiac function. Since urinary glucosewasnegative, glucoseosmouresiscan not explain the polyuria after the withdrawal of gliclazide. Dueto the spontaneous polyuria, incomplete obstruction of the urinary tract is unlikely for the mechanism of oliguria and azotemia. for renal injury which probably was in part responsible for the azotemia and the water retention. Themechanismof renal injury is not clear. Thoughthere was no allergic reaction such as rash or eosinophilia, drug-induced acute interstitial nephritis can not be ruled out. In addition to the renal injury, the abrupt polyuria maysuggest that rapidly reversible functional disturbance of water metabolism was also involved in the development of water retention. Chlorpropamide and tolbutamide have been shownto cause water retention by stimulating vasopressin secretion and by augmenting the renal action of the hormone {2-A). Hyponatremia and reduced water excretion have also been reported with glipizide, though the mechanism may differ from that seen with chlorpropamide ( 1 ). it is not known whether gliclazide has such actions or not. The plasma vasopressin concentration was appropriate for the plasma osmolality in this patient. However, there remains the possibility that gliclazide caused other functional disturbance of the water metabolism in this patient. To the best of our knowledge, this is the first report of possible gliclazide-induced water retention. We should be aware of possible water retention in patients under treatment with gliclazide.
